TrialBMC cancer2012

Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM).

Roman Hájek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.